Multidimensional Analysis of the Effects of Clonal Hematopoiesis on Heart Failure Progression

Descargo de responsabilidad

marzo 7, 2024

Centro Nacional de Investigaciones Cardiovasculares is committed to keeping this website up to date and accurate. Should you nevertheless encounter anything that is incorrect or out of date, we would appreciate it if you could let us know. Please indicate where on the website you read the information. We will then look at this as soon as possible. Please send your response by email to: hi@myoclonal.com.

We are not liable for loss as a result of inaccuracies or incompleteness, nor for loss resulting from problems caused by or inherent to the dissemination of information through the internet, such as disruptions or interruptions. When using web forms, we strive to limit the number of required fields to a minimum. For any loss suffered as a result of the use of data, advice or ideas provided by or on behalf of Centro Nacional de Investigaciones Cardiovasculares via this website, Centro Nacional de Investigaciones Cardiovasculares accepts no liability.

Any personal data you provide us with in the context of your response or request for information will only be used in accordance with our privacy statement.

All intellectual property rights to content on this website are vested in third parties who have placed the content themselves or from whom Centro Nacional de Investigaciones Cardiovasculares has obtained a user license.

Copying, disseminating and any other use of these materials is not permitted without the written permission of Centro Nacional de Investigaciones Cardiovasculares, except and only insofar as otherwise stipulated in regulations of mandatory law (such as the right to quote), unless specific content dictates otherwise.

If you have any questions or problems with the accessibility of the website, please do not hesitate to contact us.

Related Posts

Un equipo del CNIC descubre un nuevo factor de riesgo cardiovascular e identifica un fármaco capaz de reducir sus efectos

Un equipo del CNIC descubre un nuevo factor de riesgo cardiovascular e identifica un fármaco capaz de reducir sus efectos Dos estudios realizados en el CNIC aportan información relevante sobre un nuevo factor de riesgo cardiovascular, la hematopoyesis clonal, y su tratamiento con un fármaco ancestral, la colchicina A los

Read More »
News

La Fundación ”la Caixa” apuesta por el aprendizaje automático para potenciar el éxito de las inmunoterapias del cáncer

La convocatoria CaixaResearch de Investigación en Salud 2022 ha seleccionado 33 nuevos proyectos biomédicos y de salud prometedores en centros de investigación y universidades de España y Portugal. De esta manera, la Fundación ”la Caixa” reafirma una vez más su apoyo a proyectos de excelencia que puedan impactar de forma

Read More »
Fuster

José Javier Fuster: “El corazón todavía guarda muchos secretos”

El investigador coordina el estudio colaborativo MyoClonal, que busca desentrañar la relevancia de las mutaciones de las células sanguíneas en la enfermedad cardiovascular. José Javier Fuster, investigador del Centro Nacional de Investigaciones Cardiovasculares Carlos III-CNIC, coordina el estudio colaborativo MyoClonal, que busca desentrañar la relevancia de las mutaciones de las

Read More »
Logo Myoclonal Web
Ir al contenido